Literature DB >> 1774156

Propranolol treatment affects parameters of human immunity.

A S Maisel1, D Murray, M Lotz, A Rearden, M Irwin, M C Michel.   

Abstract

Elevated sympathetic activity can modulate parameters of immunity. We investigated the role of the low sympathetic activity in resting healthy volunteers by treating them with the beta-adrenergic antagonist propranolol (3 x 40 mg/d for 7 days). Propranolol treatment increased the number of circulating T cells but not that of other white blood cells. Similarly, Con A-stimulated lymphocyte proliferation and IL-2 formation were enhanced. Although the number of circulating NK cells did not change, NK-cell activity was reduced markedly after propranolol treatment. These alterations are not a mirror image of the changes observed under conditions of elevated sympathetic activity but demonstrate that withdrawal of the endogenous sympathetic tone by drugs such as propranolol can modulate parameters of human immunity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774156     DOI: 10.1016/0162-3109(91)90040-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  7 in total

Review 1.  Adhesion molecules, catecholamines and leucocyte redistribution during and following exercise.

Authors:  Roy J Shephard
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  Relation between beta-adrenergic receptor density and lymphocyte proliferation associates with acute stress.

Authors:  L Redwine; F Jenkins; A Baum
Journal:  Int J Behav Med       Date:  1996

3.  Enhancing in vivo effect of propranolol on human lymphocyte function is not due to stereospecific beta-adrenergic blockade.

Authors:  H Mangge; B Pietsch; W Lindner; H Warnkross; G Leb; K Schauenstein
Journal:  Agents Actions       Date:  1993-03

4.  Sensitization by dexamethasone of lymphocyte cyclic AMP formation: evidence for increased function of the adenylyl cyclase catalyst.

Authors:  M C Michel; J Knapp; H Ratjen
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

5.  Cytokines as new treatment targets in chronic heart failure.

Authors:  Jan Kristian Damås; Lars Gullestad; Pål Aukrust
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

Review 6.  Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.

Authors:  Daniela S Ardelean; Michelle Letarte
Journal:  Front Genet       Date:  2015-02-11       Impact factor: 4.599

7.  Propranolol Suppresses the T-Helper Cell Depletion-Related Immune Dysfunction in Cirrhotic Mice.

Authors:  Hung-Cheng Tsai; Chien-Fu Hsu; Chia-Chang Huang; Shiang-Fen Huang; Tzu-Hao Li; Ying-Ying Yang; Ming-Wei Lin; Tzung-Yan Lee; Chih-Wei Liu; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin
Journal:  Cells       Date:  2020-03-03       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.